Core Insights - Actuate Therapeutics is advancing the clinical development of elraglusib for Ewing sarcoma and potentially neuroblastoma, having received Rare Pediatric Designations from the FDA for both indications [1][3] Study Overview - The Actuate-1902 trial is an open-label, multicenter phase 1/2 study involving 40 pediatric patients aged 3 to 21 with relapsed or refractory cancers, including Ewing sarcoma and neuroblastoma [2][8] - The primary goal of the phase 1 portion was to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of elraglusib, with initial evidence of anti-tumor activity observed [8] Clinical Results - The phase 1 trial showed clinical responses in relapsed/refractory Ewing sarcoma, with two Complete Metabolic Responses (CMRs) in patients and one Complete Response (CR) in a neuroblastoma patient [6][3] - Overall, clinical responses and disease control were observed in 15 out of 40 patients with difficult-to-treat pediatric cancers, including 10 of 19 patients treated with elraglusib plus cyclophosphamide/topotecan [6][7] Future Plans - The company plans to initiate additional clinical trials in 2026 to expedite a registration pathway for elraglusib in Ewing sarcoma and potentially advance its use in neuroblastoma [4][3] - Collaborative development programs are being assessed with leading pediatric consortia and Key Opinion Leaders to align future studies with patient needs and regulatory expectations [3] Mechanism of Action - Elraglusib is a novel GSK-3β inhibitor that targets molecular pathways involved in tumor growth and resistance to conventional cancer therapies, potentially mediating anti-tumor immunity [12]
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers